Although multiple strategies, including enzyme replacement therapy, gene therapy, chaperone therapy, and substrate reduction therapy are being explored for MPS6, none are available to patients with MPS IIIC. The gene discussed is ARSB; the disease is mucopolysaccharidosis type 3C.